Evidence map›Paper›PMID 37494371›Full record

ArticlePloS one2023

Wild mouse gut microbiota limits initial tuberculosis infection in BALB/c mice.

Min Xie, Chen-Yu Tsai, Zachary L McAdams, Myo Oo, Mark Hansen, Maureen Dougher, Alexander Sansano, Anderson Watson, Katherine LoMauro, Rosleine Antilus-Sainte and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. The Probiotic Effects ofInternational journal of microbiology · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Min XieCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.ORCID 0000-0002-9770-5351
Chen-Yu TsaiCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Zachary L McAdamsMolecular Pathogenesis and Therapeutics Program, University of Missouri, Columbia, Missouri, United States of America.ORCID 0000-0003-2883-507X
Myo OoCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Mark HansenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.ORCID 0000-0003-0567-180X
Maureen DougherCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Alexander SansanoCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.ORCID 0000-0003-2360-6446
Anderson WatsonCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Katherine LoMauroCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Rosleine Antilus-SainteCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Aaron EricssonMolecular Pathogenesis and Therapeutics Program, University of Missouri, Columbia, Missouri, United States of America.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.
Martin GengenbacherCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States of America.ORCID 0000-0002-0208-5920
Hackensack Meridian Health · USUniversity of Missouri · US

Funding

Viable but Nonculturable MtbU19AI111143 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W, GLICKMAN, MICHAEL S · 2014 to 2020
$48.6M
Pharmacology & ImmunoPathology (PIP) CoreU19AI162568 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE · 2021 to 2025
$13.0M
MOLECULAR BASIS OF GENE EXPRESSION AND SIGNAL PROCESSINGT32GM008396 · NIGMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI HANNINK, MARK · 1991 to 2021
$4.1M
NIAID NIH HHS U19 AI111143NIAID NIH HHS U19 AI162568NIGMS NIH HHS T32 GM008396
6 · The paper itself

Abstract

Mouse models are critical tools in tuberculosis (TB) research. Recent studies have demonstrated that the wild mouse gut microbiota promotes host fitness and improves disease resistance. Here we examine whether the wild mouse gut microbiota alters the immunopathology of TB in BALB/c mice. Conventional BALB/c mice (LabC) and mice born to germ-free BALB/c mothers reconstituted with the wild mouse gut microbiota (WildR) were used in our studies. WildR mice controlled initial TB infection better than LabC mice. The microbial gut communities of LabC mice and WildR mice had similar richness but significantly different composition prior to infection. TB reduced the gut community richness in both cohorts while differences in community composition remained indicating a general TB-induced dysbiosis. The wild mouse gut microbiota did not alter the typical lung histopathology of TB in the BALB/c model that includes unstructured immune cell infiltrates with infected foamy macrophages invading alveolar spaces. Animals of both cohorts mounted robust T cell responses in lungs and spleen with lower absolute counts of CD4 and CD8 T cells in lungs of WildR mice during acute infection, corresponding with observed differences in pathogen load. In summary, LabC mice and WildR mice showed largely overlapping TB immunopathology and pathogen kinetics, with WildR mice controlling early acute infection better than LabC mice.

Indexed as

Gastrointestinal MicrobiomeLatent TuberculosisTuberculosisAnimalsDysbiosisLungMiceMice, Inbred BALB C

Identifiers

PMID37494371
PMCPMC10370681
OpenAlexW4385269036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.